Closed-loop neurostimulation offers a new treatment approach for drug-resistant epilepsy, with implanted electrodes monitoring abnormal discharges in real time and automatically delivering suppressive stimulation. This topic covers clinical trials and device regulatory progress.
September 2026
Epilepsy Neuromodulation Moves Toward Closed-Loop Sensing and Less Invasive Implants
Preprint: Self-Updating Models Predict All Seizures in 75% of Patients Amid Drift
Researchers showed that seizure-prediction methods lose much of their accuracy in continuous use, with mean AUROC dropping from 90% offline to 57.9% online across 664.9 hours of intracranial EEG from 16 patients with drug-resistant epilepsy, because brain signals drift over time. An online evolutionary framework that keeps selecting and updating models on the data stream predicted every seizure in 75% of patients and missed only one in 87.5%. Reading only contacts in the epileptogenic network cut the required contacts by 79.12%. The team has released the dataset. The study is a preprint and has not been peer reviewed.
Implant-Grade BCI Preserves Epilepsy HFO Biomarkers, Maps Onset Zone at 84% Sensitivity
A wireless implantable neural interface, the Brain Interchange (BIC), paired with artifact-removal algorithms captured about 82% of the high-frequency oscillations (HFOs) that a clinical-grade amplifier detected across 24-hour intracranial EEG recordings in 10 patients with drug-resistant epilepsy, according to a preprint. Using those HFOs, the system localized the seizure onset zone with 84% sensitivity and 90% specificity, comparable to clinical equipment. The authors present the work as a translational framework for chronic tracking of epileptogenic networks and for future biomarker-guided adaptive neuromodulation.
August 2026
Mayo Clinic Team Pairs CorTec Implant With BCI2000, Records Stably in Dogs for 3+ Years
A Mayo Clinic team integrated CorTec's Brain Interchange (BIC), an implantable neural sensing and stimulation device, with the open-source BCI2000 software platform to create an open research system for developing and testing implantable brain-computer interfaces and closed-loop neuromodulation, in which the device reads brain signals and adjusts stimulation accordingly. In long-term validation in 5 dogs, with the longest implant exceeding 3 years, the system maintained stable chronic recording, documented gradual degradation of some channels and its mechanical causes, and still decoded brain function more than 2 years after implantation. The team also showed one-dimensional cursor control was feasible in 1 human participant and released its surgical, imaging and analysis protocols and data. The work is a preprint and has not been peer reviewed.
Chinese Hospitals Test Closed-Loop BCI Neuromodulation for Resistant Depression
A multicenter trial has begun in China to test closed-loop brain-computer interface neuromodulation for treatment-resistant depression, run jointly by the Shanghai Mental Health Center and two Beijing hospitals, Anding Hospital and Xuanwu Hospital. The study will compare closed-loop deep brain stimulation and transcutaneous auricular vagus nerve stimulation against sham stimulation, enrolling patients who have responded inadequately to standard antidepressant treatment. It uses a patient-preference design with randomized assignment within each intervention group.
FDA Clears FIND Neuro CN-Suite Localization Tool
The US Food and Drug Administration cleared CN-Suite, source localization software from FIND Surgical Sciences Inc., doing business as FIND Neuro, on August 16, 2026, finding it substantially equivalent under submission number K260563 via the Traditional 510(k) pathway. FDA lists the device as Source Localization Software for Electroencephalograph or Magnetoencephalograph, a Class II device under regulation number 882.1400, reviewed by the agency's neurology advisory committee. Such software works back from electrical or magnetic fields recorded at the scalp to the intracranial origin of the signal, supporting presurgical planning such as locating epileptic foci.
July 2026
Deep Learning Localizes Epileptogenic Zones
The researchers developed a deep learning architecture that analyzes multichannel interictal intracranial EEG to localize epileptogenic zones without requiring seizure-period recordings or manual annotation. The model combines a Morlet-wavelet temporal Transformer with a spatial attention encoder. It was evaluated with 50.5 hours of recordings from 161 patients and 17,012 channels at 7 independent centers. Leave-one-center-out validation produced a pooled AUROC of 0.778 with a 95% confidence interval of 0.748 to 0.808, and discrimination remained above chance at every held-out center. The results indicate performance comparable to established electrophysiological baselines across centers and implantation modalities, but prospective clinical validation is still needed. This medRxiv preprint has not been peer reviewed.
ECoG Network Features Predict Seizure Risk
Nova Southeastern University researchers combine intracranial ECoG network features with a support vector machine and Bayesian updating for real-time continuous seizure risk forecasting.
June 2026
FDA Clears Ceribell Monitor for Bedside EEG Recording
The FDA cleared the Ceribell Monitor on June 30, 2026, finding it substantially equivalent under submission number K261101 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. It is one of several Ceribell clearances in the same period; the product line is built around rapid reduced-montage setup for bedside recording in emergency and critical care.
FDA Clears Ceribell Neurology Review Software
The FDA cleared the Ceribell Neurology Review Software on June 24, 2026, finding it substantially equivalent under submission number K260998 through the traditional 510(k) pathway. The agency classifies it as Automatic Event Detection Software for Full-Montage Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. The category covers software that automatically flags events within full-montage EEG recordings, surfacing candidate segments from long records for clinician review.
February 2026
FDA Clears PreOp v3 Source Localization Tool
The FDA cleared Clouds of Care's PreOp v3 on February 13, 2026, finding it substantially equivalent under submission number K252565 through the special 510(k) pathway. The agency classifies it as Source Localization Software for Electroencephalograph or Magnetoencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Source localization software infers the intracranial origin of signals from scalp-recorded electric or magnetic fields, a step in neurosurgical planning such as presurgical localization of epileptic foci.
December 2025
FDA Clears Ceribell Delirium Monitor System
The FDA cleared the Ceribell Delirium Monitor System on December 8, 2025, finding it substantially equivalent under submission number K251936 through the traditional 510(k) pathway. The agency classifies it as a Neuropsychiatric Interpretative Electroencephalograph Assessment Aid, a Class II device under regulation 882.1440, with neurology as the assigned review panel. The category covers devices that derive neuropsychiatric assessments from EEG signals; Ceribell's earlier products in this line target seizure monitoring in emergency and intensive care settings.
November 2025
FDA Clears Ceribell Infant Seizure Software
The US Food and Drug Administration cleared Ceribell, Inc.'s Ceribell Infant Seizure Detection Software on November 21, 2025, finding it substantially equivalent under submission number K252070 via the Traditional 510(k) pathway. FDA lists it as Automatic Event Detection Software for Full-Montage Electroencephalograph, a Class II device under regulation number 882.1400, reviewed by the agency's neurology advisory committee. Neonatal EEG looks markedly different from adult morphology, which has long made automated interpretation difficult; the classification covers software that flags events automatically in full-montage recordings.
February 2024
China's Neuracle Registers 96-Patient Trial of Closed-Loop Epilepsy Implant
Chinese registry ChiCTR2400081380 describes a 96-patient trial of an implantable closed-loop recording and stimulation system for focal drug-resistant epilepsy in people aged 6 to 70. All participants are to receive the implant and then be randomized one month later to active or sham stimulation, 48 per group. The registry provides no evidence that enrollment had passed 50%.